Synthesis of mesoporous silica nanoparticles with organotin and folic acid: Influence of PEG concentration in the formulation
Source abstract
Abstract
Nanotechnology is gaining prominence in biomedicine due to its ability to address diseases like breast cancer through highly effective nanomaterials. Their unique physicochemical properties enable the encapsulation of therapeutic agents and targeted delivery, minimizing side effects of conventional treatments. In this study, a tin(IV) compound was used for its anticancer activity, while folic acid served as a targeting agent due to its affinity for tumor cell membranes. To overcome common issues such as nanoparticle aggregation and poor aqueous dispersion, formulations with varying concentrations of N-(triethoxysilylpropyl)-o-polyethylene oxide urethane (PEG) were developed. The materials were characterized, and their performance in biological media was assessed. Cytotoxicity was tested in the MCF-7 breast cancer cell line, and toxicity was evaluated in Hek 293T cells. Among the tested nanomaterials, the final materials functionalized with 5% of the polymer, exhibited the best antitumor activity, highlighting their potential for furtherin vivodevelopment in cancer therapy.Graphical abstract
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Polyoxometalates: Synthesis and Applications · Mesoporous Materials and Catalysis · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (72)
Show source-provided references
1. H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021). https://doi.org/10.3322/caac.2166010.3322/caac.21660 ↗
2. F. Bray, M. Laversanne, H. Sung, J. Ferlay, R.L. Siegel, I. Soerjomataram et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 (2024). https://doi.org/10.3322/caac.2183410.3322/caac.21834 ↗
3. R.L. Siegel, K.D. Miller, N.S. Wagle, A. Jemal, Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023). https://doi.org/10.3322/caac.2176310.3322/caac.21763 ↗
4. Z. Yu, X. Bai, R. Zhou, G. Ruan, M. Guo, W. Han et al., Differences in the incidence and mortality of digestive cancer between global cancer observatory 2020 and global burden of disease 2019. Int. J. Cancer 154, 615–625 (2024). https://doi.org/10.1002/ijc.3474010.1002/ijc.34740 ↗
5. A.N. Giaquinto, H. Sung, K.D. Miller, J.L. Kramer, L.A. Newman, A. Minihan et al., Breast cancer statistics, 2022. CA: A Cancer J. Clin. 72, 524–41 (2022). https://doi.org/10.3322/caac.2175410.3322/caac.21754 ↗
6. E.H. Bae, M.K. Greenwald, A.G. Schwartz, Chemotherapy-induced peripheral neuropathy: mechanisms and therapeutic avenues. Neurotherapeutics 18, 2384–2396 (2021). https://doi.org/10.1007/s13311-021-01142-210.1007/s13311-021-01142-2 ↗
7. N.C. Miltenburg, W. Boogerd, Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat. Rev. 40, 872–882 (2014). https://doi.org/10.1016/j.ctrv.2014.04.00410.1016/j.ctrv.2014.04.004 ↗
8. K. Gupta, R. Walton, S.P. Kataria, Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat. Res. Commun. 26, 100278 (2021). https://doi.org/10.1016/j.ctarc.2020.10027810.1016/j.ctarc.2020.100278 ↗
9. D. Glover, V. Harmer, Radiotherapy-induced skin reactions: assessment and management. Br. J. Nurs. (2014). https://doi.org/10.12968/bjon.2014.23.Sup2.S2810.12968/bjon.2014.23.Sup2.S28 ↗
10. N. Kuptsova, J. Chang-Claude, S. Kropp, I. Helmbold, P. Schmezer, D. von Fournier et al., Genetic predictors of long-term toxicities after radiation therapy for breast cancer. Int. J. Cancer 122, 1333–1339 (2008). https://doi.org/10.1002/ijc.2313810.1002/ijc.23138 ↗
11. G. Curigliano, D. Cardinale, S. Dent, C. Criscitiello, O. Aseyev, D. Lenihan et al., Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J. Clin. 66, 309–325 (2016). https://doi.org/10.3322/caac.2134110.3322/caac.21341 ↗
12. L. Galluzzi, L. Senovilla, I. Vitale, J. Michels, I. Martins, O. Kepp et al., Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869–1883 (2012). https://doi.org/10.1038/onc.2011.38410.1038/onc.2011.384 ↗
13. P.B. Tchounwou, S. Dasari, F.K. Noubissi, P. Ray, S. Kumar, Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy. J. Exp. Pharmacol. 13, 303–328 (2021). https://doi.org/10.2147/JEP.S26738310.2147/JEP.S267383 ↗
14. T. Makovec, Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol. Oncol. 53, 148–158 (2019). https://doi.org/10.2478/raon-2019-001810.2478/raon-2019-0018 ↗
15. J. da Silva Prade, R.S. de Souza, C.M. de Silva D’Avila, T.C. da Silva, I.C. Livinalli, A.C.Z. Bertoncelli et al., An overview of renal cell carcinoma hallmarks, drug resistance, and adjuvant therapies. Cancer Diagn. Progn. 3, 616–34 (2023). https://doi.org/10.21873/cdp.1026410.21873/cdp.10264 ↗
16. S.A. Elsayed, I.M. Elnabky, M.M. Aboelnga, A.M. El-Hendawy, Palladium(II), platinum(II), and silver(I) complexes with 3-acetylcoumarin benzoylhydrazone Schiff base: synthesis, characterization, biomolecular interactions, cytotoxic activity, and computational studies. RSC Adv. 14, 19512–19527 (2024). https://doi.org/10.1039/D4RA02738H10.1039/D4RA02738H ↗
17. S.K. Raju, A. Karunakaran, S. Kumar, P. Sekar, M. Murugesan, M. Karthikeyan, Silver complexes as anticancer agents: a perspective review. German J. Pharmaceuticals Biomater. 1, 6–28 (2022). https://doi.org/10.5530/gjpb.2022.1.310.5530/gjpb.2022.1.3 ↗
18. S.J. Berners-Price, A. Filipovska, Gold compounds as therapeutic agents for human diseases. Metallomics 3, 863–873 (2011). https://doi.org/10.1039/C1MT00062D10.1039/C1MT00062D ↗
19. T.S. Reddy, S.H. Privér, R. Ojha, N. Mirzadeh, G.R. Velma, R. Jakku et al., Gold(I) complexes of the type [AuL{κC-2-C6H4P(S)Ph2}] [L = PTA, PPh3, PPh2(C6H4-3-SO3Na) and PPh2(2-py)]: Synthesis, characterisation, crystal structures, and In Vitro and In Vivo anticancer properties. Eur. J. Med. Chem. 281, 117007 (2025). https://doi.org/10.1016/j.ejmech.2024.11700710.1016/j.ejmech.2024.117007 ↗
20. P.M. Abeysinghe, M.M. Harding, Antitumour bis(cyclopentadienyl) metal complexes: titanocene and molybdocene dichloride and derivatives. Dalton Trans. (2007). https://doi.org/10.1039/B707440A10.1039/B707440A ↗
21. M. Cini, T.D. Bradshaw, S. Woodward, Using titanium complexes to defeat cancer: the view from the shoulders of titans. Chem. Soc. Rev. 46, 1040–1051 (2017). https://doi.org/10.1039/C6CS00860G10.1039/C6CS00860G ↗
22. C.N. Banti, S.K. Hadjikakou, T. Sismanoglu, N. Hadjiliadis, Anti-proliferative and antitumor activity of organotin(IV) compounds. An overview of the last decade and future perspectives. J. Inorg. Biochem. 194, 114–52 (2019). https://doi.org/10.1016/j.jinorgbio.2019.02.00310.1016/j.jinorgbio.2019.02.003 ↗
23. S.N. Syed Annuar, N.F. Kamaludin, N. Awang, K.M. Chan, Cellular basis of organotin(IV) derivatives as anticancer metallodrugs: a review. Front. Chem. (2021). https://doi.org/10.3389/fchem.2021.65759910.3389/fchem.2021.657599 ↗
24. Y.A. Adekunle, B.B. Samuel, L. Nahar, A.A. Fatokun, S.D. Sarker, Cytotoxic triterpenoid saponins from the root of Olax subscorpioidea Oliv. (Olacaceae). Phytochemistry 215, 113853 (2023). https://doi.org/10.1016/j.phytochem.2023.11385310.1016/j.phytochem.2023.113853 ↗
25. N.A. Abd Aziz, N. Awang, K.M. Chan, N.F. Kamaludin, N.N. Mohamad Anuar, Organotin (IV) dithiocarbamate compounds as anticancer agents: a review of syntheses and cytotoxicity studies. Molecules 28, 5841 (2023). https://doi.org/10.3390/molecules2815584110.3390/molecules28155841 ↗
26. L. Chen, L. Wang, W. An, R. Wang, L. Tian, Synthesis, structural characterization, and antibacterial activity of diorganotin complexes of Schiff base derived from 4-(diethylamino) salicylaldehyde and L-tyrosine. Inorg. Nano-Metal Chem. 50(9), 872–879 (2020). https://doi.org/10.1080/24701556.2020.172751510.1080/24701556.2020.1727515 ↗
27. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, R. Langer, Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech. 2, 751–760 (2007). https://doi.org/10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
28. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65, 271–284 (2000). https://doi.org/10.1016/s0168-3659(99)00248-510.1016/s0168-3659(99)00248-5 ↗
29. V. Torchilin, Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 63, 131–135 (2011). https://doi.org/10.1016/j.addr.2010.03.01110.1016/j.addr.2010.03.011 ↗
30. A.C. Antony, The biological chemistry of folate receptors. Blood 79, 2807–2820 (1992)10.1182/blood.V79.11.2807.2807 ↗
31. N. Parker, M.J. Turk, E. Westrick, J.D. Lewis, P.S. Low, C.P. Leamon, Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 338, 284–293 (2005). https://doi.org/10.1016/j.ab.2004.12.02610.1016/j.ab.2004.12.026 ↗
32. M. Ahmadi, C.A. Ritter, T. von Woedtke, S. Bekeschus, K. Wende, Package delivered: folate receptor-mediated transporters in cancer therapy and diagnosis. Chem. Sci. 15(6), 1966–2006 (2024). https://doi.org/10.1039/D3SC05539F10.1039/D3SC05539F ↗
33. I.I. Slowing, J.L. Vivero-Escoto, C.W. Wu, V.S.Y. Lin, Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv. Drug Deliv. Rev. 60(11), 1278–1288 (2008). https://doi.org/10.1016/j.addr.2008.03.01210.1016/j.addr.2008.03.012 ↗
34. F.D.S. Bruckmann, F.B. Nunes, T.D.R. Salles, C. Franco, F.C. Cadoná, C.R. Bohn Rhoden, Biological applications of silica-based nanoparticles. Magnetochemistry 8(10), 131 (2022). https://doi.org/10.3390/magnetochemistry810013110.3390/magnetochemistry8100131 ↗
35. F. da Silva Bruckmann, A.C. Pimentel, A.R. Viana, T. da Rosa Salles, L.M.F. Krause, S.R. Mortari, I.Z. da Silva, C.R.B. Rhoden, Synthesis, characterization and cytotoxicity evaluation of magnetic nanosilica in L929 cell line. Disciplinarum Sci. Naturais e Tecnol. 21(3), 1–14 (2020). https://doi.org/10.37779/nt.v21i3.363110.37779/nt.v21i3.3631 ↗
36. V. Mamaeva, C. Sahlgren, M. Lindén, Mesoporous silica nanoparticles in medicine–recent advances. Adv. Drug Deliv. Rev. 65, 689–702 (2013). https://doi.org/10.1016/j.addr.2012.07.01810.1016/j.addr.2012.07.018 ↗
37. P. Kolimi, S. Narala, A.A.A. Youssef, D. Nyavanandi, N. Dudhipala, A systemic review on development of mesoporous nanoparticles as a vehicle for transdermal drug delivery. Nanotheranostics 7, 70–89 (2023). https://doi.org/10.7150/ntno.7739510.7150/ntno.77395 ↗
38. J.M. Rosenholm, C. Sahlgren, M. Lindén, Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles—opportunities & challenges. Nanoscale 2, 1870–1883 (2010). https://doi.org/10.1039/C0NR00156B10.1039/C0NR00156B ↗
39. B. Xu, S. Li, R. Shi, H. Liu, Multifunctional mesoporous silica nanoparticles for biomedical applications. Sig. Transduct. Target Ther. 8, 1–28 (2023). https://doi.org/10.1038/s41392-023-01654-710.1038/s41392-023-01654-7 ↗
40. Q. He, Z. Zhang, Y. Gao, J. Shi, Y. Li, Intracellular localization and cytotoxicity of spherical mesoporous silica nano- and microparticles. Small 5, 2722–2729 (2009). https://doi.org/10.1002/smll.20090092310.1002/smll.200900923 ↗
41. C. Bharti, U. Nagaich, A.K. Pal, N. Gulati, Mesoporous silica nanoparticles in target drug delivery system: a review. Int J Pharm Investig 5, 124–133 (2015). https://doi.org/10.4103/2230-973X.16084410.4103/2230-973X.160844 ↗
42. Y. Zhang, J. Wang, X. Bai, T. Jiang, Q. Zhang, S. Wang, Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs. Mol. Pharm. 9, 505–513 (2012). https://doi.org/10.1021/mp200287c10.1021/mp200287c ↗
43. J.V. Jokerst, T. Lobovkina, R.N. Zare, S.S. Gambhir, Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond.) 6, 715–728 (2011). https://doi.org/10.2217/nnm.11.1910.2217/nnm.11.19 ↗
44. M. Koohi Moftakhari Esfahani, S.E. Alavi, P.J. Cabot, N. Islam, E.L. Izake, Application of mesoporous silica nanoparticles in cancer therapy and delivery of repurposed anthelmintics for cancer therapy. Pharmaceutics 14, 1579 (2022)10.3390/pharmaceutics14081579 ↗
45. J. Wang, X. Fang, W. Liang, Pegylated phospholipid micelles induce endoplasmic reticulum-dependent apoptosis of cancer cells but not normal cells. ACS Nano 6, 5018–5030 (2012). https://doi.org/10.1021/nn300571c10.1021/nn300571c ↗
46. C.Z. Bueno, C.A. Oliveira, C.O. Rangel-Yagui, 17 - Polymeric and liposomal nanomaterials, in Nanobiomaterials. ed. by R. Narayan (Woodhead Publishing, 2018), pp.437–6410.1016/B978-0-08-100716-7.00017-9 ↗
47. E. Mehdipoor, M. Adeli, M. Bavadi, P. Sasanpour, B. Rashidian, A possible anticancer drug delivery system based on carbon nanotube–dendrimer hybrid nanomaterials. J. Mater. Chem. 21, 15456–15463 (2011). https://doi.org/10.1039/C1JM13254G10.1039/C1JM13254G ↗
48. N.K. Mal, M. Fujiwara, Y. Tanaka, Photocontrolled reversible release of guest molecules from coumarin-modified mesoporous silica. Nature 421, 350–353 (2003). https://doi.org/10.1038/nature0136210.1038/nature01362 ↗
49. A. Popat, S.B. Hartono, F. Stahr, J. Liu, S.Z. Qiao, G.Q. Lu, Mesoporous silica nanoparticles for bioadsorption, enzyme immobilisation, and delivery carriers. Nanoscale 3, 2801–18 (2011). https://doi.org/10.1039/C1NR10224A10.1039/C1NR10224A ↗
50. M. Vallet-Regí, F. Balas, D. Arcos, Mesoporous materials for drug delivery. Angew. Chem. Int. Ed. 46, 7548–7558 (2007). https://doi.org/10.1002/anie.20060448810.1002/anie.200604488 ↗
51. Q. He, J. Shi, F. Chen, M. Zhu, L. Zhang, An anticancer drug delivery system based on surfactant-templated mesoporous silica nanoparticles. Biomaterials 31, 3335–3346 (2010). https://doi.org/10.1016/j.biomaterials.2010.01.01510.1016/j.biomaterials.2010.01.015 ↗
52. F. Tang, L. Li, D. Chen, Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv. Mater. 24, 1504–1534 (2012). https://doi.org/10.1002/adma.20110476310.1002/adma.201104763 ↗
53. R. Liu, X. Zhao, T. Wu, P. Feng, Tunable Redox-Responsive Hybrid Nanogated Ensembles. J. Am. Chem. Soc. 130, 14418–14419 (2008). https://doi.org/10.1021/ja806088610.1021/ja8060886 ↗
54. F.M. Veronese, G. Pasut, PEGylation, successful approach to drug delivery. Drug Discov. Today 10, 1451–1458 (2005). https://doi.org/10.1016/S1359-6446(05)03575-010.1016/S1359-6446(05)03575-0 ↗
55. K.B. Horwitz, M.E. Costlow, W.L. McGuire, MCF-7; a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors. Steroids 26, 785–795 (1975). https://doi.org/10.1016/0039-128x(75)90110-510.1016/0039-128x(75)90110-5 ↗
56. P.Y. Liyanage, S.D. Hettiarachchi, Y. Zhou, A. Ouhtit, E.S. Seven, C.Y. Oztan et al., Nanoparticle-mediated targeted drug delivery for breast cancer treatment. Biochim. Biophys. Acta Rev. Cancer 1871, 419–433 (2019). https://doi.org/10.1016/j.bbcan.2019.04.00610.1016/j.bbcan.2019.04.006 ↗
57. M. Gisbert-Garzarán, M. Vallet-Regí, Influence of the surface functionalization on the fate and performance of mesoporous silica nanoparticles. Nanomaterials 10, 916 (2020). https://doi.org/10.3390/nano1005091610.3390/nano10050916 ↗
58. K.S.W. Sing, Reporting physisorption data for gas/solid systems with special reference to the determination of surface area and porosity (Recommendations 1984). Pure Appl. Chem. 57, 603–619 (1985). https://doi.org/10.1351/pac19855704060310.1351/pac198557040603 ↗
59. N.L. McFarlane, N.J. Wagner, E.W. Kaler, M.L. Lynch, Calorimetric study of the adsorption of poly(ethylene oxide) and poly(vinyl pyrrolidone) onto cationic nanoparticles. Langmuir 26, 6262–6267 (2010). https://doi.org/10.1021/la904046g10.1021/la904046g ↗
60. V. García-Almodóvar, P. del Rosario Ardiles, S. Prashar, P. Laura Páez, S. Gómez-Ruiz, Unleashing the antibacterial and antibiofilm potential of silica-based nanomaterials functionalized with an organotin( iv ) compound. J. Mater. Chem. B 12, 9056–9073 (2024). https://doi.org/10.1039/D4TB01106F10.1039/D4TB01106F ↗
61. L.M. Ng, R. Simmons, Infrared spectroscopy. Anal. Chem. 71, 343–350 (1999). https://doi.org/10.1021/a1999908r10.1021/a1999908r ↗
62. I.M. Deygen, E.V. Kudryashova, New versatile approach for analysis of PEG content in conjugates and complexes with biomacromolecules based on FTIR spectroscopy. Colloids Surf., B 141, 36–43 (2016). https://doi.org/10.1016/j.colsurfb.2016.01.03010.1016/j.colsurfb.2016.01.030 ↗
63. F. Olmo, A. Rodriguez, A. Colina, A. Heras, F. Olmo, A. Rodriguez et al., UV/Vis absorption spectroelectrochemistry of folic acid. J. Solid State Electrochem. 26, 29–37 (2022). https://doi.org/10.1007/S10008-021-05026-510.1007/S10008-021-05026-5 ↗
64. V. García-Almodóvar, K. Ovejero-Paredes, D. Díaz-García, J.M. Méndez-Arriaga, S. Prashar, M. Filice et al., Albumin-loaded silica nanomaterials functionalized with organotin(IV) agents: theranostic materials against triple-negative breast cancer. Adv. Ther. 7, 2400114 (2024). https://doi.org/10.1002/adtp.20240011410.1002/adtp.202400114 ↗
65. K. Ovejero Paredes, D. Díaz-García, V. García-Almodóvar, L. Lozano Chamizo, M. Marciello, M. Díaz-Sánchez et al., Multifunctional silica-based nanoparticles with controlled release of organotin metallodrug for targeted theranosis of breast cancer. Cancers (Basel) 12, 187 (2020). https://doi.org/10.3390/cancers1201018710.3390/cancers12010187 ↗
66. Y. Zhang, Y. Wang, R. Wang, Y. Shen, J. Xu, T.J. Webster et al., Personalized nanomedicine: a rapid, sensitive, and selective UV-vis spectrophotometry method for the quantification of nanostructured PEG-asparaginase activity in children’s plasma. Int. J. Nanomed. 13, 6337–6344 (2018). https://doi.org/10.2147/IJN.S16738010.2147/IJN.S167380 ↗
67. M. Ugalde-Arbizu, J.J. Aguilera-Correa, V. García-Almodóvar, K. Ovejero-Paredes, D. Díaz-García, J. Esteban et al., Dual anticancer and antibacterial properties of silica-based theranostic nanomaterials functionalized with coumarin343, folic acid and a cytotoxic organotin(IV) metallodrug. Pharmaceutics 15, 560 (2023). https://doi.org/10.3390/pharmaceutics1502056010.3390/pharmaceutics15020560 ↗
68. K. Ovejero-Paredes, D. Díaz-García, I. Mena-Palomo, M. Marciello, L. Lozano-Chamizo, Y.L. Morato et al., Synthesis of a theranostic platform based on fibrous silica nanoparticles for the enhanced treatment of triple-negative breast cancer promoted by a combination of chemotherapeutic agents. Biomater. Adv. 137, 212823 (2022). https://doi.org/10.1016/j.bioadv.2022.21282310.1016/j.bioadv.2022.212823 ↗
69. S. Zalba, T.L.M. Ten Hagen, C. Burgui, M.J. Garrido, Stealth nanoparticles in oncology: facing the PEG dilemma. J. Control. Release 351, 22–36 (2022). https://doi.org/10.1016/j.jconrel.2022.09.00210.1016/j.jconrel.2022.09.002 ↗
70. S. Zaichik, C. Steinbring, M. Jelkmann, A. Bernkop-Schnürch, Zeta potential changing nanoemulsions: impact of PEG-corona on phosphate cleavage. Int. J. Pharm. 581, 119299 (2020). https://doi.org/10.1016/j.ijpharm.2020.11929910.1016/j.ijpharm.2020.119299 ↗
71. Y. Zhang, M. Yang, N.G. Portney, D. Cui, G. Budak, E. Ozbay et al., Zeta potential: a surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells. Biomed. Microdev. 10, 321–328 (2008). https://doi.org/10.1007/s10544-007-9139-210.1007/s10544-007-9139-2 ↗
72. Y. Zhao, B.G. Trewyn, I.I. Slowing, V.S.-Y. Lin, Mesoporous silica nanoparticle-based double drug delivery system for glucose-responsive controlled release of insulin and cyclic AMP. J. Am. Chem. Soc. 131, 8398–400 (2009). https://doi.org/10.1021/ja901831u10.1021/ja901831u ↗